A bdominal aortic aneurysm (AAA) is a serious and common pathologic abnormality that accompanies aging. Among men older than 65 years, the prevalence of AAA reaches 7.7%, increasing from 5.7% in ages 64-69 years to 8.9% in individuals older than 74 years (1). The high overall mortality from ruptured AAAs makes growth and subsequent rupture risk assessment crucial for AAA management.Since the 1970s, many studies (2) have demonstrated that AAA diameter correlates with rupture rate. Accordingly, AAA maximum diameter, effectively measured by using diagnostic US, has been the primary prognostic variable used to determine patient care (3,4). Current guidelines dictate elective repair to be appropriate at a diameter threshold of 50-55 mm or for AAA exhibiting growth greater than 1 cm per year (5,6).However, whereas some AAAs smaller than 55 mm do not grow more than 1 cm per year (7), other AAAs that are too small to trigger intervention grow rapidly. The sole use of maximal diameter measurement may be insufficient to
Central venous access is necessary in patients candidate for peripheral blood stem cell (PBSC) collection. We report our experience with a dual lumen femoral catheter (Gamcath, 11 french), initially designed for hemodialysis. We studied 147 patients and performed 488 collections after mobilization with either G-CSF alone or chemotherapy + G-CSF, when the white blood cell count exceeded 1 x 10(9)/L, or when a measurable population of CD34+ cells (20/microL) was detected in peripheral blood. All patients received systemic anticoagulation with a low weight heparin and ultrasound examination was performed after the removal of the catheter. Seven patients developed thrombosis (4.7%), ten experienced hematomas at the site of catheter placement (6.8%) despite prophylactic platelet transfusions, while only one patient (0.6%) had a catheter-related infection. In conclusion, the short-term use of large bore femoral catheters in setting up PBSC collection seems to be associated with minimal risk of infection and low thrombotic incidence.
Neck angulation (NA) is an important risk factor for type 1 proximal endoleaks following stenting of abdominal aortic aneurysms. The Aorfix (Lombard Medical, Oxon, UK) is a new flexible stent graft designed to overcome this issue. The aim of this study was to compare the endoleak flow rate (EFR) in relation to NA between the Aorfix and other manufactured stent grafts. A flow model with silicone proximal and distal necks was used. EFRs corresponding to 10 neck angles between 0 and 70 degrees were measured. Eight stent grafts were tested: Aorfix, Ancure (Guidant, Indianapolis, IN), Powerlink (Endologix, Irvine, CA), AneuRx (Medtronic, Sunnyvale, CA), Excluder (W.L. Gore & Associates, Flagstaff, AZ), Zenith and Zenith-Flex (Cook Inc., Bloomington, IN), and Lifepath (Edwards Lifesciences, Irvine, CA). For all stent grafts except the Aorfix, the EFR was greater than at baseline for NA >or= 30 degrees (p < .01). The EFR at NA >or= 30 degrees was lower with the Aorfix compared with the other stent grafts (p < .01). NA had no influence on the EFR with the Aorfix. The Aorfix may decrease the incidence of proximal type 1 endoleak in patients with a severely angulated aortic neck.
Klippel-Trenaunay (KT) syndrome is a vascular malformation characterized by a port-wine stain, varicose veins and hypertrophy of the affected limb. Ulceration is considered an uncommon complication of KT syndrome and occurrence of skin cancer has been previously reported only in one case. We observed a case of KT syndrome in a 48-year-old woman who developed a large ulcer and a squamous cell carcinoma on the affected leg.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.